CytoTools AG represents a strong commitment to values and corporate philosophy. The company focuses on innovation, scientific expertise, and patient-centric strategies to develop and commercialize innovative healthcare products. CytoTools AG aims to improve the quality of life for patients through targeted therapies and solutions. With a dedicated team of professionals, the company emphasizes transparency, integrity, and ethical practices. By fostering collaborations and strategic partnerships, CytoTools AG strives to make a significant impact on the healthcare industry.

CytoTools AG is primarily present in Germany, where its headquarters are located. As a biotechnology company, CytoTools AG focuses on developing and commercializing innovative drugs in the field of diseases related to the immune system. While Germany is its primary market, CytoTools AG also operates in other countries and regions within Europe. The company aims to expand its presence globally by collaborating with partners and conducting clinical trials in various regions. By leveraging its expertise and research advancements, CytoTools AG aims to improve healthcare outcomes and provide innovative solutions for immune-related diseases worldwide.

CytoTools AG has achieved significant milestones, positioning itself as a leading company in the field. Some notable accomplishments include successful clinical trials for several drug candidates, gaining regulatory approvals and patents for innovative therapies. The company's commitment to research and development has resulted in breakthroughs in treating various diseases, enhancing its reputation within the pharmaceutical industry. Furthermore, CytoTools AG's strong financial performance, strategic partnerships, and global expansion efforts have contributed to its continued growth and success. These achievements solidify CytoTools AG's position as a frontrunner, driving advancements in the medical sector.

CytoTools AG, a Germany-based biotechnology company, has a rich history and a strong background in the field. Established in 2002, CytoTools focuses on developing innovative drugs and medical devices for various therapeutic areas, particularly in the treatment of infectious diseases and cancer. The company is renowned for its expertise in the development of new drugs and medical approaches based on its proprietary "Low-Level-Redox-Signaling" (LLRS) technology platform. With a dedicated team of scientists, CytoTools continuously strives to improve patient care and aims to bring new and effective treatment options to the market. This commitment to innovation and medical advancement has positioned CytoTools AG as a significant player in the biotechnology sector.

The main competitors of CytoTools AG in the market include companies such as Actelion Pharmaceuticals Ltd, Bayer AG, Pfizer Inc., and Novartis International AG.

CytoTools AG is primarily active in the pharmaceutical and biotechnology industries.

The business model of CytoTools AG is focused on developing and commercializing innovative drugs and medical devices for the treatment of various diseases. CytoTools AG aims to improve patient outcomes by creating therapies that target unmet medical needs. The company primarily focuses on dermatological, urological, and gynecological indications. CytoTools AG combines scientific research, development, and manufacturing capabilities to bring novel healthcare solutions to market. With a dedication to advancing patient care, CytoTools AG continues to explore new opportunities and collaborations to expand its portfolio of products.

De bioXXmed K/W is -7,08.

De bioXXmed KUV is 0,04.

De AlleAktien Kwaliteitsscore voor bioXXmed is 3/10.

De verwachte bioXXmed omzet is 138,39 mln. EUR.

De verwachte bioXXmed winst is -824.160,04 EUR.

CytoTools AG is a German company specializing in the research and development of medications for the treatment of skin diseases, inflammation, and cancer. The company has been listed on the stock exchange since 2006 and is headquartered in Darmstadt. Its activities are divided into four business areas: 1. Dermatology: CytoTools AG focuses on the development and marketing of medications for the treatment of skin diseases such as acne, eczema, and psoriasis. The company is particularly focused on the development of the CertoCyte® platform technology, which can deliver the active ingredient directly to the affected skin layer. 2. Immunology: CytoTools AG researches medications for the treatment of inflammatory diseases caused by immune system dysregulation. The goal is to alleviate symptoms and slow down the progression of the disease. This includes autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. 3. Oncology: In the field of oncology, CytoTools AG conducts research on medications for the treatment of various types of cancer. The focus is on the development of substances that specifically target cancer cells without affecting healthy cells. The company aims to increase the efficacy of cancer treatment through the combination of different active ingredients. 4. Diagnostics: CytoTools AG focuses on the development of diagnostics for the early detection of cancer and other diseases. This includes the development of rapid tests that enable the detection of tumor cells in blood or urine. The goal is to accelerate diagnosis and improve treatment options for patients. Overall, CytoTools AG offers various products and technologies that are available on the market. These include DermaPro®, a medication used for the treatment of psoriasis, and CutiMed®, an active ingredient used for acne and rosacea. Additionally, CytoTools AG also provides various laboratory services, including the validation of new active ingredients. The business model of CytoTools AG is based on the development of new medications and technologies for the treatment of skin diseases, inflammatory diseases, and cancer. By combining different active ingredients and platform technologies, the effectiveness of therapy is intended to be enhanced. CytoTools AG follows a holistic approach that spans from research and development to clinical trials and the marketing of products. As a publicly listed company, CytoTools AG relies on successful business development and good cooperation with its partners. To further advance research projects and promote new developments, the company collaborates closely with universities and research institutes. The goal is to develop innovative products and technologies that drive medical progress and improve the lives of patients.

bioXXmed keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor bioXXmed of het bedrijf keert geen dividend uit.

De ISIN van bioXXmed is DE000A0KFRJ1.

Het WKN van bioXXmed is A0KFRJ.

De ticker van bioXXmed is T5O.DE.

Binnen de laatste 12 maanden betaalde bioXXmed een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal bioXXmed naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van bioXXmed is momenteel .

bioXXmed betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

bioXXmed betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

bioXXmed wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van bioXXmed van 22-9-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 22-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 22-9-2024.

In het jaar 2023 heeft bioXXmed 0 EUR aan dividenden uitgekeerd.

De dividenden van bioXXmed worden in EUR uitgekeerd.